Independent
Tenure on this board
0.3 yrs
Also a director at
Matinas Biopharma Holdings Inc (MTNB)
2 nominees · 8 ballot items.
Election of two directors; approval of issuance/conversion of Preferred Stock (change of control, related party, and issuance approvals); approval of reverse stock split (1-for-2 to 1-for-199); increase authorized common stock; permit stockholder written consent; and adjournment if necessary.
Elect Jerome Jabbour as Class I director and Matthew McMurdo as Class III director for terms expiring 2028 and 2027, respectively.
Approve issuance of common stock upon conversion of Series AA and Series AAA Preferred Stock (collectively, Preferred Stock) in accordance with Nasdaq Listing Rule 5635(b), which would result in significant ownership by the investor.
Approve issuance of common stock upon conversion of Preferred Stock to David E. Lazar (Chairman and Co-CEO) under Nasdaq Listing Rule 5635(c) due to potential equity compensation treatment.
Approve issuance of common stock upon conversion of Preferred Stock under Nasdaq Listing Rule 5635(d) because conversion would equal 19.99% or more of outstanding common stock at a price below Nasdaq Minimum Price.
Approve amendment to Charter to permit Board to effect up to two reverse stock splits at an aggregate ratio of 1-for-2 to 1-for-199, with the Board selecting the ratio within the range to increase per-share price.
Approve amendment to Charter to increase authorized common stock from 200,000,000 to up to 1,000,000,000 shares.
Approve amendment to Charter to allow stockholder action by written consent (unanimous consent provision), subject to rights of preferred holders.
Authorize proxy holders to adjourn or postpone the Special Meeting to solicit additional proxies if needed to establish quorum or approve proposals 1–7.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 0.0% | 39,018 | $71K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 26,292 | $48K |
| 3 | MORGAN STANLEY | 0.0% | 2,697 | $5K |
| 4 | Tower Research Capital LLC (TRC | 0.0% | 1,890 | $3K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 715 | $1K |
| 6 | SBI Securities Co., Ltd. | 0.0% | 17 | $31 |
| 7 | CWM, LLC | 0.0% | 2 | $4 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.